Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 27, 2020 at 05:39 am EDT
Share
Zhejiang Xinguang Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 212.577 million compared to CNY 213.143 million a year ago. Operating income was CNY 87.226 million compared to CNY 81.763 million a year ago. Net income was CNY 75.224 million compared to CNY 69.251 million a year ago. Basic earnings per share from continuing operations was CNY 0.47 compared to CNY 0.43 a year ago.
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.